Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

P.A. Ascierto, M. Del Vecchio, C. Robert, A. Mackiewicz, V. Chiarion-Sileni, A. Arance, C. Lebbé, L. Bastholt, O. Hamid, P. Rutkowski, C. McNeil, C. Garbe, C. Loquai, B. Dreno, L. Thomas, J.-J. Grob, G. Liszkay, M. Nyakas, R. Gutzmer, J. PikielF. Grange, C. Hoeller, V. Ferraresi, M. Smylie, D. Schadendorf, L. Mortier, I.M. Svane, D. Hennicken, A. Qureshi, M. Maio, Massimo Guidoboni

Research output: Contribution to journalArticle

Cite this

Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., ... Guidoboni, M. (2017). Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology, 18(5), 611-622. https://doi.org/10.1016/S1470-2045(17)30231-0